Targovax awarded an immuno-oncology innovation prize

Targovax is one of the winners of Immuno-Oncology Innovation Projects, awarded by Oslo Cancer Cluster and Innovation Norway, in competition with many other high quality projects. 

The prize consists of a grant amounting to 0,4 million NOK. It will contribute to the funding of Targovax’s development of new cancer vaccines, with focus on the new peptide vaccine TG03 for treatment of RAS mutated malignant melanoma. 

Targovax is proud to receive this prize and wants to thank Oslo Cancer Cluster and Innovation Norway for the grant. This is a great acknowledgement and support of Targovax’s work to develop the new cancer vaccines in pipeline towards clinical testing. 

The company in brief 

Targovax AS is a Norwegian company founded in 2010 by world pioneers in cancer immunotherapy, based on a substantial body of data from non-clinical and clinical research. Targovax AS develops active immunotherapy in the form of cancer specific therapeutic vaccines. The vaccines stimulate the patients’ immune system to recognize and kill cancer cells having mutations in the RAS genes. There is a large unmet need for treatment of cancers with RAS mutations. The lead product TG01 is under clinical development for the treatment of resected pancreatic cancer.